Moderna To Build A State Of The Art MRNA Facility In Kenya
Africa Trending

Moderna To Build A State Of The Art MRNA Facility In Kenya

Reading Time: 3 minutes

The state-of-the-art mRNA facility in Africa is expected to produce up to 500 million doses of vaccines each year

President Uhuru Kenyatta today in State House, Nairobi witnessed the signing of a memorandum of understanding between Kenya and Moderna to establish the first mRNA manufacturing facility in Africa.

The state-of-the-art mRNA facility in Africa is expected to produce up to 500 million doses of vaccines each year. Modernananticipates investing up to $500 million in the new facility, which will focus on drug substance manufacturing on the continent of Africa for the continent of Africa.

President Kenyatta has been at the forefront championing for the African continent to manufacture its own COVID-19 vaccines in order to meet the demand of its population. His Excellency has always emphasized the fact that Africa’s capacity to manufacture vaccines would help arrest emerging pandemics.

The President pointed out that the setting up of the mRNA manufacturing facility will be a game-changer, especially for Kenya which has had the vision to produce vaccines.

“We are celebrating one of the greatest things that has possibly happened since the onset of COVID-19 at the African continent,” said President Kenyatta when he spoke.

The President reiterated the challenges faced by the African continent during the COVID-19 pandemic. This was not because of a lack of finances to buy the vaccines but because the vaccines were not available for them for purchase.

His Excellency thanked Moderna for investing in the continent that has suffered trying to meet its vaccine needs saying. He stressed the significance of a new facility that will go a long way in enabling African countries to tackle any emerging future pandemics.

Battling the COVID-19 pandemic over the last two years has provided a reminder of the work that must be done to ensure global health equity

“We all know the challenges that Kenya and the entire continent of Africa went through in the earlier stages of this pandemic that resulted in Africa being left behind. Not because of want but because of lack and Moderna has come to fill that space.

“We are truly grateful, for this and I think it will be transformative not just in helping us with the current pandemic but also preparing the continent of Africa for future pandemics,” President Kenyatta said.

The President thanked the Director for the Africa Centre for Disease Control Dr. John Nkengasong and the Government of America for supporting Kenya in its endeavour to set up the facility.

“Thank you for the support we have received from you (Dr. John Nkengasong) and your entire team from Africa CDC. I would also want to thank the American Government that has also been very supportive to Kenya and Africa not only to make this day happen but also for the support they gave us of vaccines at a time we needed them,” he added

“Battling the COVID-19 pandemic over the last two years has provided a reminder of the work that must be done to ensure global health equity. Moderna is committed to being a part of the solution and today, we announce another step in this journey – an investment in the Republic of Kenya to build a drug substance mRNA manufacturing facility capable of supplying up to 500 million doses for the African continent each year,” said Stéphane Bancel, Chief Executive Officer of Moderna.

He added the mRNA global public health vaccine program, which includes vaccine programs against HIV and Nipah, will ensure sustainable access to transformative mRNA innovation on the African continent.

Director for Africa Centre for Disease Control Dr. John Nkengasong affirmed the setting up of a facility is critical to Africa’s security. The production of the vaccines will ensure the continent is able to tackle current and future health challenges.

TDS News
TDS News
News does not and should not dehumanize people for the sake of financial gains, political favours and social media clout.